|
C4ORF41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.80149999865031E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35539999948742E-07 |
| Normal-vs-Stage2 |
1.170320E-02 |
| Normal-vs-Stage3 |
3.18939999965906E-07 |
| Normal-vs-Stage4 |
4.95529950406137E-10 |
| Stage1-vs-Stage2 |
1.255580E-01 |
| Stage1-vs-Stage3 |
1.440400E-01 |
| Stage1-vs-Stage4 |
5.397000E-03 |
| Stage2-vs-Stage3 |
3.273500E-02 |
| Stage2-vs-Stage4 |
8.830000E-04 |
| Stage3-vs-Stage4 |
1.367180E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.55099999299813E-09 |
| Normal-vs-AfricanAmerican |
7.825000E-03 |
| Normal-vs-Asian |
1.70801999999082E-05 |
| Caucasian-vs-AfricanAmerican |
2.859600E-01 |
| Caucasian-vs-Asian |
8.867200E-01 |
| AfricanAmerican-vs-Asian |
3.827800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.92210000050342E-07 |
| Normal-vs-Female |
4.76589999687249E-08 |
| Male-vs-Female |
8.639800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.55510000011373E-07 |
| Normal-vs-Age(41-60Yrs) |
1.24669999990168E-07 |
| Normal-vs-Age(61-80Yrs) |
1.7653999999645E-06 |
| Normal-vs-Age(81-100Yrs) |
9.618000E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.955000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.081000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.056000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.007600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.079000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.188800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.231900E-02 |
| Classical-VS-Follicular |
1.047590E-01 |
| Classical-VS-Other |
2.713800E-01 |
| Classical-VS-Normal |
1.11450000006563E-07 |
| Tall-VS-Follicular |
8.021400E-04 |
| Tall-VS-Other |
9.328000E-01 |
| Tall-VS-Normal |
8.02970000490788E-08 |
| Follicular-VS-Other |
1.616770E-01 |
| Follicular-VS-Normal |
6.122200E-03 |
| Other-VS-Normal |
2.978800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.68910000003719E-06 |
| Normal-vs-N1 |
4.50500003967846E-09 |
| N0-vs-N1 |
2.454100E-02 |
|
|
